聯康生物科技集團(00690.HK)上半年營業額增132.8%至1.57億港元 首次實現純核心業務錄得利潤
格隆匯8月27日丨聯康生物科技集團(00690.HK)發佈公吿,截至2021年6月30日止六個月,集團營業額錄得1.57億港元,按年增長132.8%。集團首次實現純核心業務錄得利潤。集團期內錄得溢利190萬港元,而去年同期則錄得1150萬港元虧損。
期內,一般及行政開支佔營業額百分比由29.0%減至14.2%。銷售及分銷開支佔營業額百分比由63.1%減少14.6個百分點至48.5%。匹納普®期內收益由約1570萬港元大幅增長257.3%至約5610萬港元。匹納普®於2021年2月獲納入國家集中採購,帶動其銷售顯著增長。金因肽®及金因舒®營業額表現強勁,其銷售分別增長116.8%及45.8%。
集團於2021年第一季開始生產博舒泰®,其銷售於期內為集團帶來即時收益貢獻。期內,集團籌備第二代Uni-PTH水針橋接臨牀試驗及Uni-GLP臨牀試驗相關工作,預計於2021年下半年開展。集團與多特生物達成戰略合作,為視網膜疾病患者共同研發多特異性多特體。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.